

RECEIVED

JUL 25 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
CONTINUED PROSECUTION APPLICATION (CPA)  
REQUEST TRANSMITTAL  
(only for Continuation or Divisional applications under 37 CFR 1.53(d))

Docket No.: 176/60197 (6-11405-675/676)  
Express Mail No.: EI989354428US  
Examiner: Larry R. Helms, Ph.D.  
Art Unit: 1642

Commissioner for Patents  
Washington, D.C. 20231  
BOX: CPA

This is a Request for filing a:

- ☒ continuation or  
☐ divisional application

under 37 CFR 1.53(d), continued prosecution application, (CPA) of prior application number 09/016,743, filed on January 30, 1998, of Joseph D. Rosenblatt, Pia Challita-Eid, Sherie L. Morrison, Camille N. Abboud, Seung-Uon Shin entitled CHIMERIC ANTIBODY FUSION PROTEINS FOR THE RECRUITMENT AND STIMULATION OF AN ANTITUMOR IMMUNE RESPONSE.

The above-identified prior pending application is hereby expressly abandoned as of the filing date of this request for a continued prosecution application (CPA).

1. ☐ Enter the unentered amendment previously filed on [\*enter date] under 37 CFR 1.116 in the prior nonprovisional application.
2. ☒ A preliminary amendment is enclosed.
3. ☐ This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53 (d)(4).
  - a. ☐ Delete the following inventor(s) named in the prior nonprovisional application:  
  
\_\_\_\_\_  
  
\_\_\_\_\_  
  
\_\_\_\_\_
- b. ☐ The inventor(s) to be deleted are set forth on a separate sheet enclosed herewith.
4. ☐ A new power of attorney is enclosed herewith.
5. ☐ Information Disclosure Statement (IDS) with PTO-1449 form(s) and copies of references are enclosed herewith.
6. The filing fee is calculated on the basis of the claims existing in the prior application as amended above:

07/24/2002 AWONDAF1 00000129 09016743

01 FC:231

370.00 OP

	(Col. 1)	(Col. 2)	SMALL ENTITY			LARGE ENTITY	
FOR:	NO. FILED	NO. EXTRA	RATE	FEE	OR	RATE	FEE
BASIC FEE	XXXXXXXXXX	XXXXXXXXXX	XXXXXX	\$370	OR	XXXXXX	\$740
TOTAL CLAIMS	10 - 20 =	0	x 9 =	\$	OR	x 18 =	\$
INDEP CLAIMS	1 - 3 =	0	x 42 =	\$	OR	x 84 =	\$
[ ] MULTIPLE DEPENDENT CLAIM PRESENTED			x140 =	\$	OR	x280 =	\$
*If the Total Claims are less than 20 and Indep. Claims are less than 3, enter "0" in Col. 2			TOTAL	\$370	OR	TOTAL	\$


7. [X] A check in the amount of **\$370.00** is enclosed to cover the above filing fee.
8. [X] The Commissioner is hereby authorized to charge fees which may be required, or credit overpayment to Deposit Account No. 14-1138. A duplicate copy of this sheet is enclosed.
9. Small entity status:
  - [X] Applicants claim small entity status. (See 37 CFR 1.27.)
  - [ ] A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.
  - [ ] is no longer claimed.
10. [X] A copy of the Request for Four-Month Extension of Time in prior application.
11. [X] Declaration Of Seung-Uon Shin Under 37 C.F.R. § 1.132 (4 pages) with Appendix A-E.
12. [X] A self-addressed, prepaid postcard for acknowledging receipt.
13. Other:

Address all future communications to (may only be completed by Applicant, or attorney or agent of record):

Michael L. Goldman  
NIXON PEABODY LLP  
Clinton Square  
P.O. Box 31051  
Rochester, New York 14603-1051

Respectfully submitted,

Date: July 19, 2002

  
Michael L. Goldman  
Registration No. 30,727

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603  
Telephone: (585) 263-1304  
Facsimile: (585) 263-1600  
R601711.1

E JC35  
Jul 19 2002  
PATENT & TRADEMARK OFFICE

PATENT  
Docket No.: 176/60197 (6-11405-675/676)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Rosenblatt et al.  
Serial No. : CPA of 09/016,743  
Cnfrm. No. : 7389  
Filed : Herewith  
For : CHIMERIC ANTIBODY FUSION  
PROTEINS FOR THE RECRUITMENT  
AND STIMULATION OF AN  
ANTITUMOR IMMUNE RESPONSE

Examiner:  
Larry R. Helms: Ph.D.

Art Unit:  
1642

# 54/c  
KS  
727-02

PRELIMINARY AMENDMENT

U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202  
Box: CPA

Dear Sir:

In response to the final rejection, please amend the above-identified application as follows:

In the Claims:

Please cancel claims 11-24 and 26-76 without prejudice. Please amend claim 1 as follows:

1. (Thrice Amended) A chimeric molecule suitable for stimulating a tumor specific immune response comprising:  
a complete antibody having heavy and light chains each with an N terminus and being capable of specifically binding to a tumor cell associated antigen, and  
a chemokine, which is coupled to the N terminus of the heavy or light chain of the antibody such that the antibody remains capable of binding to the tumor cell associated antigen and the chemokine retains activity.

Does it  
or it  
not  
C

only 1 char  
not 2  
chemokine